The Wolverine stack is two peptides doing the same job

The Wolverine stack pairs BPC-157 with TB-500 and sells the pairing as more than the sum of the parts. Read the mechanistic literature on each and the opposite is true. Both compounds converge on the same two steps of repair, new blood vessels and cells migrating into the wound, in the same rodent models. That is redundancy wearing the costume of synergy.

Nobody has run the study that could tell the two apart, which is a problem the nickname does nothing to solve.

What is in the stack

BPC-157 is a stable gastric pentadecapeptide, a sequence derived from a protein found in gastric juice, described across a long series of papers from Sikiric and colleagues.^[1]

15 amino acids in BPC-157, which is what pentadecapeptide means PMID 31158953

TB-500 is not thymosin beta-4. It corresponds to an active-site fragment, and Sosne and colleagues showed in 2010 that the parent peptide’s activities map onto exactly such short sequences.^[2] The full peptide is what carries the clinical evidence, and the fragment is what people inject.

Overlap one: both are sold on new blood vessels

Angiogenesis is the headline mechanism for each compound independently.

• Seiwerth and colleagues reviewed BPC 157 and blood vessels in 2014, describing angiogenic and vascular responses across preclinical work.^[3] Rats throughout.
• A 2018 review of thymosin beta-4 and the vasculature describes multiple roles in vessel development, repair and protection against injury.^[4] Also preclinical.

If your case for stacking is “one builds vessels and the other does something else”, the literature does not support the second half of that sentence. Both are vascular stories.

Overlap two: both are sold on cells moving into the wound

The second mechanism is the same shape.

Thymosin beta-4 binds actin through the beta-thymosin module and participates in the cytoskeletal regulation that makes a cell able to crawl at all.^[5] That is about as direct a migration mechanism as biology offers.

BPC-157 lands in the same place from a different direction. Chang and colleagues reported in 2011 that pentadecapeptide BPC 157 promoted tendon healing in culture through tendon outgrowth, cell survival and cell migration.^[6] Cultured tendon cells, and migration again.

Both mechanisms feed the same bottleneck. Reviews of wound repair describe recruitment and migration of cells into the wound as an early step in the process,^[7] which means the two compounds are queued at the same door rather than opening different ones.

The mechanistic problem: two agents pushing on the same step do not produce two effects. They produce more of one effect, up to whatever ceiling that step has, and nobody has measured where that ceiling is for either compound.

The closest everyday analogy is taking ibuprofen and naproxen together. Both inhibit the same enzymes. You do not get two kinds of pain relief, you get more of one mechanism and more of its risk profile, which is why no clinician stacks them.

Where the human evidence stops

Each half of the stack fails the human test at a different point, and both fail it.

BPC-157. Vasireddi and colleagues published a systematic review of BPC-157 in orthopaedic sports medicine in 2025 and found the evidence base rests on animal studies.^[8] The full picture of what is and is not known sits in BPC-157 Side Effects: The Safety Data Nobody Has.

TB-500. The randomized human trial in this family used a 0.1% thymosin beta-4 ophthalmic solution against corneal healing endpoints, in patients with damaged corneal nerves.^[9] Everything else is animal work: Philp and Kleinman’s 2010 review covers thymosin beta as a multifunctional tissue repair molecule across animal studies.^[10]

0.1% the thymosin beta-4 concentration in its randomized human trial, given as an eye drop PMID 36613994

A stack cannot have better evidence than its components. We compared the two head to head in TB-500 vs BPC-157: Which Has the Better Evidence, and neither wins on human data because neither has any.

Why “they work together” is an untested sentence

Synergy is a technical claim with a specific test attached to it. Montgomery, Peters and Little set out the standard in 2003: a factorial randomised trial, which tests each intervention alone and both together in the same experiment.^[11] Without those arms you cannot distinguish synergy from additivity, from one compound doing all the work, from neither doing anything.

No such trial exists for BPC-157 and TB-500. Not in humans, not in rats.

The peptide literature does contain a warning about assuming combinations behave predictably. Jain and Roy coassembled collagen and laminin short peptides into a scaffold and got material behaviour that neither peptide produced alone.^[12] Combination changed the result, and the direction of change is not something you can reason your way to from the components. The same reasoning applies to the three-peptide GLOW version of this idea.

What is being sold: a nickname, attached to two compounds whose published mechanisms overlap, neither of which has a controlled human trial for tendon or muscle repair.

The study that would settle it

Four arms, and it is not an exotic design:

1. Placebo.
2. BPC-157 alone.
3. TB-500 alone.
4. Both together.

Run that in humans with a healing endpoint anyone can measure, and the question closes in one trial. Until somebody does, “they work synergistically” describes a hope about two rodent literatures that were never compared.

The comic book character regenerates because the writers say so. The stack works the same way.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.